and poor prognosis of GBM. Although combined treatments, including surgical resection, radiotherapy, chemotherapy, and immunotherapy, achieve a measure of progress, the late-stage outcomes of GBM are not encouraging due to high metastasis and invasiveness. 3 Therefore, seeking out new molecules correlated to GMB progression is of extreme urgency.
Long noncoding RNAs (lncRNAs), a group of nonprotein coding transcriptions with a length of more than 200 nt, are extensively involved in various diseases including cancer. 4 Long noncoding RNAs work as oncogenes or anti-oncogenes and participate in various aspects of cancer-related cell events including epithelial-mesenchymal transition, apoptosis, cancer stem cell differentiation, cell proliferation, and metastasis. [5] [6] [7] [8] [9] He et al reported that lncRNA urothelial carcinoma associated 1 interacted with microRNA (miR)-182 to modulate glioma proliferation and migration by targeting inhibitor of the apoptosis-stimulating protein of p53 (iASPP). 10 Kang et al found that
lncRNA RP5-833A20.1 inhibited U251 cell proliferation, metastasis, and cell cycle progression by suppressing the expression of nuclear factor IA. 11 Based on a previous genome-wide analysis of lncRNA expression in GBM (GSE104267), we found that lncRNA AC016405.3, a novel lncRNA also named RP11-44N11.2, was significantly downregulated in GBM. Low expression of AC016405.3 was closely related to an aggressive phenotype and poor prognosis of patients with GBM. These findings also indicated that AC016405.3 might be an anti-oncogene in GBM. Up to the present, related research on the expression and function of AC016405.3 in GBM has been rare.
Long noncoding RNAs are well known to exert their functions through a mechanism of competing endogenous RNA (ceRNA). It is supposed that RNA transcripts communicate with others through "talking" with a new "language" mediated by miRNA response elements (MREs). 12, 13 Qin et al reported that lncRNA MEG3 inhibited glioma cell proliferation, migration, and invasion by acting as a ceRNA of miR-19a. 14 Xiao et al reported that lncRNA TP73-AS1 suppressed glioma growth and metastasis by working as a ceRNA through miR-124-dependent inhibitor of iASPP regulation. 15 Until now, it has been unclear whether AC016405.3 can act as a ceRNA and cowork with any miRNAs in GBM.
In the present study, AC016405.3 was shown to work as an anti-oncogene in GBM. AC016405.3 suppressed GBM cell proliferation and metastasis by miR-19a sponging to modulate ten-eleventranslocation-2 (TET2).
| MATERIAL S AND ME THODS

| Patients and tissue samples
The present research was granted approval by the Institute Research
Medical Ethics Committee of Dalian Medical University (Dalian, China). Formal written informed consent was provided by the patients whose tissues were used in the present study. Three freshly frozen GBM tissues and paired paratumor tissue specimens as well as 64 formalin-fixed paraffin-embedded GBM specimens (from July 2012 to November 2016) were collected from the First Affiliated
Hospital of Dalian Medical University. All GBM tissue samples were graded according to the 2007 WHO classification by two neuropathologists: grade I and II (n = 30), and grade III and IV (n = 34).
| Cell culture
A human GBM cell line U87MG was purchased from Shanghai 
| Reverse transcription and quantitative realtime PCR
The procedure was carried out as previously reported. 16 Total RNAs were extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA). Quantitative PCRs were carried out by using a SYBR Green PCR Kit (Takara, Dalian, China) on a CFX96 Touch sequence detection system (Bio-Rad, Hercules, CA, USA). GAPDH and U6 were applied to internal controls of lncRNAs and TET2 mRNA, and miRNAs, respectively. Expression levels of targeted genes were calculated by the 2 −ΔΔCt method. 17 Specific primers for each targeted gene were chemically synthesized by RiboBio (Guangzhou, China) and listed in Table S1 .
| In situ hybridizations assay and immunohistochemistry assay
In situ hybridization (ISH) was undertaken by applying an ISH Kit (Boster Bio-Engineering Company, Wuhan, China) as previously described. 18 Formalin-fixed paraffin-embedded GBM tissue slices were deparaffinized and deproteinated. Slices were prehybridized in a prehybridization solution at 42°C for 2 hours and incubated with a DIG-labeled specific probe targeting AC016405.3 (RiboBio) at 42°C overnight. After strictly washing, the slides were then exposed to a streptavidin-peroxidase reaction system and stained with 3, 3′diam-inobenzidine (ZSGB-BIO, Beijing, China). Hematoxylin was used to counterstain the slices. All slices were observed and photographed under a microscope (Leica, Wetzlar, Germany).
The immunohistochemistry procedure was carried out as previously described. Figure S1 ). MicroRNA-19a-5p
shRNAs (shmiR-19a-5p1# and shmiR-19a-5p 2#) and control shRNA (shCtrl) were chemically synthesized by RiboBio. In order to gain a miR-19a-5p stable knockdown cell line, U87MG and U251 MG cells after transfection were selected by the culture medium containing 0.4 mg/mL Geneticin (G418; Invitrogen). After 6 weeks, G418-resistant cell clones were established. Total RNAs from these cell lines were extracted for further microarray analysis. analyzed. Differentially expressed genes were chosen based on the following criteria: fold change >2 and P < .05. The hierarchical clustering analysis was carried out on the differentially expressed genes.
| Microarray analysis
F I G U R E 1 AC016405.3 was downregulated and correlated with poor prognosis in patients with glioblastoma multiforme (GBM). A, Expression of 10 long noncoding RNAs (lncRNAs) in 3 GBM tissue specimens and paired adjacent normal brain tissue specimens was measured by quantitative RT-PCR assay. B, AC016405.3 was downregulated in GBM tissue specimens according to an lncRNA expression profile of GSE104267. PH_lnc_0016010 represented for AC016405.3. C, Quantitative RT-PCR assay indicated that AC016405.3 was downregulated in 61 of 64 GBM tissue specimens. D, Mean optical density of AC016405.3 was gradually decreased with advanced staging as checked by an in situ hybridization assay. ***P < .001 vs paratumor group. E, Kaplan-Meier analyses showed that the overall survival of GBM patients with low AC016405.3 was shorter than that with high AC016405.3. F, AC016405.3 was also downregulated in GBM cell lines. Data were shown as mean ± SD from 3 independent experiments. **P < .01 vs normal human astrocyte (NHA) group
| Western blot analysis
Total proteins from GBM cells were extracted by a RIPA lysis buffer (Beyotime, Shanghai, China) and qualified by a BCA detecting kit (Beyotime). Protein samples were subjected to 10% SDS-PAGE and transferred onto PVDF membranes (Millipore, Billerica, MA, USA).
The membranes were incubated with specific Abs targeting TET2
(Abcam, Cambridge, MA, UK; dilution rates of 1:250) and GAPDH (Abcam; dilution rates of 1:500) at 4°C overnight, separately. The next day, the membranes were incubated with a secondary Ab (Abcam; dilution rates of 1:2000) at room temperature for 1 hour.
The protein expression images were obtained through a BioSpectrum Gel Imaging System (UVP, Upland, CA, USA).
| Cell counting assay
We applied the CCK-8 assay as previously reported to determine the proliferation ability changes of GBM cells. 
| Wound-healing assay and Transwell assay
For the wound-healing assay, U87MG and U251MG cells were seed 
was involved in AC016405.3-mediated suppression of proliferation and metastasis in U87MG and U251MG cells. A, Expressions] of miRNAs in 3 glioblastoma multiforme (GBM) tissue specimens and paired adjacent normal brain tissue specimens were determined by quantitative RT-PCR assay. B, MiR-19a-5p was upregulated in GBM tissue specimens according to the miRNA expression profile of GEO dataset GSE103228. 42549 represented for miR-19a-5p. C, MiR-19a-5p was upregulated in GBM cell lines U87MG and U251MG compared to normal human astrocytes (NHA). **P < .01 vs NHA group. D, Expression of miR-19a-5p was inversely correlated with AC016405.3. E, Upregulation and downregulation of AC016405.3 inversely regulated miR-19a-5p expression. **P < .01 vs vector or scramble siRNA (siSCR) group, separately. F, Up-and downregulation of miR-19a-5p negatively regulated AC016405. **P < .01 vs negative control (NC) mimic or NC inhibitor group, individually. G,H, Upregulation of AC016405 suppressed U87MG (G) and U251MG (H) cell proliferation, but the inhibitive effect was abrogated by enhancement of miR-19a-5p, determined by a -assay. I,J, Upregulation of AC016405 suppressed U87MG (G) and U251MG (H) cell metastasis, but the inhibitive effect was attenuated by an increase of miR-19a-5p, determined by wound healing and Transwell assays, respectively. P > .05 and **P < .01 vs AC016405 group. n.s., not significant. K, Diagram of constructed luciferase reporter plasmids. L, Cotransfection of a WT reporter plasmid (AC016405-luc-wt) and miR-19a-5p mimics resulted in a significant weakening of luminescence as compared with cotransfection of AC016405-luc-wt and NC mimic. While the theoretical miRNA response elements (MREs)-19a-5p in AC016405 was mutated (cotransfection of AC016405-luc-mut and miR-19a-5p mimics), the luminescence was restrengthened. and Data are shown as mean ± SD from 3 independent experiments. **P < .01 vs NC mimic group. n.s., P > .05 visualize wound healing. The percentage of wound closure (original width − width after cell migration) / original width was calculated.
For the Transwell assay, the procedure was carried out as previously described. 21 In short, GBM cells were incubated on uncoated (for migration assays) and Matrigel-coated (for invasion assays)
upper chambers (BD Biosciences, Franklin Lakes, NJ, USA), respectively. Culture medium not containing or containing 10% FBS was supplemented into the upper and lower wells individually and cultured for a further 24 hours, after which the non-migrated and non-invaded cells were wiped out. Then, the filters were fixed in 90% alcohol, followed by crystal violet staining. Five random fields were counted per chamber with an inverted microscope (Olympus, Tokyo, Japan).
| Dual luciferase reporter assay
The procedure was carried out as previously described. 18 Wild and mutant reporter plasmids of AC016405.3 (AC016405.3-luc-wt and AC016405.3-luc-mut) and TET2 (TET2-luc-wt1 and TET2-luc-mut1, TET2-luc-wt2 and TET2-luc-mut2, TET2-luc-wt3 and TET2-luc-mut3, TET2-luc-wt4 and TET2-luc-mut4, TET2-luc-wt5
and TET2-luc-mut5) were purchased from GenePharma. When 
| Statistical analysis
All data were collected from 3 independent repeated experiments and expressed as mean ± SD. Statistical analysis was determined by Differences between 2 groups were analyzed by Student's t test. Oneway ANOVA was used for analyzing differences among multiple sets of data. Differences were considered significant if *P < .05, **P < .01, or ***P < .0001, individually.
| RE SULTS
| AC016405.3 downregulated and correlated with poor prognosis in GBM patients
According to a previous genome-wide lncRNA microarray analysis in GBM (GSE104267), 13 downregulated lncRNAs with criteria of LogFC < −2 and P < .001 were primarily screened out (Table S2 ). Among them, we measured the expression of 10 lncRNAs whose lengths were <1000 bp in 3 collected freshly frozen GBM tissue specimens and 3 paired adjacent normal brain tissue specimens. As shown in the data presented in Figure 1A , AC016405.3 was stably downregulated in all 3 of the paired GBM tissue specimens, and was therefore selected for the following research. Furthermore, AC016405.3 also showed downregulation in 9 GBM samples compared to 3 normal brain samples according to an analysis of GEO dataset GSE104267 ( Figure 1B) . Additionally, the expression of AC016405.3 in 64 paraffin-embedded GBM tissues was determined. As the results in Figure 1C show, AC016405.3 was downregulated in most (95.31%, 61/64) GBM tissues. We also analyzed the expression of AC016405.3 in different grades of GBM tissue specimens by ISH analysis. As the representative photographs reveal in Figure 1D , the expression of AC016405.3 was gradually downregulated with an advanced grading (P < .001). Clinically, we analyzed the correlation between elevated AC016405.3 and the clinicopathological features of patients with GBM. As displayed in Figure 1E and Table 1, low expression of AC016405.3 was closely correlated with a shorter survival rate (determined by a Kaplan-Meier analysis, P = .014), a larger diameter (P = .002), a higher pathological grading (P = .000), and more frequent distant metastasis (P = .012). Finally, we detected the expression of AC016405.3 at a cellular level. As the findings of qRT-PCR show ( Figure 1F ), compared with NHA, AC016405.3 was downregulated in 2 GBM cell lines, U87MG and U251MG.
| Upregulation of AC016405.3 suppressed proliferation and metastasis in U87MG and U251MG cells
In this section, we undertook gain-of-function experiments to explore the role of AC016405.3 played in GBM. First, AC016405.3 was upregulated in U87MG and U251 cells by transfecting AC016405.3-overexpressing plasmid (Figure 2A,B) . Then, we used a CCK-8 assay to detect the proliferative ability changes of U87MG and U251MG Figure 2C ,D, upregulation of AC016405.3 F I G U R E 4 MicroRNA (miR)-19a-5p promoted proliferation and metastasis by targeting suppression of TET2 in U87MG and U251MG cells. A, Hierarchical clustering analysis of mRNAs that were differentially expressed between test (miR-19a-5p knocked down) and control (>2.0-fold; P < .05; filtered to show the upregulated or downregulated mRNAs). Expression values are represented in shades of red and green, indicating expression above and below the median expression value across all samples, respectively. B, TET2 was downregulated in glioblastoma multiforme (GBM) tissue specimens compared with that in paratumor tissue specimens, determined by immunohistochemistry assay. ***P < .001 vs paratumor group. C,D, Up-and downregulation of miR-19a-5p (C) inversely regulated TET2 protein expression (D). ***P < .001 vs negative control (NC) mimic or NC inhibitor group, individually. E,F, Upregulation of miR-19a-5p promoted U87MG (E) and U251MG (F) cell proliferation, but the facilitative effect was remarkably abolished by a TET2 overexpression plasmid (oeTET2), checked by a CCK-8 assay. G,H, Upregulation of miR-19a-5p promoted U87MG and U251MG cell metastasis, but the promotive effect was remarkably attenuated by an increase of TET2 as measured by a wound healing assay (G) and a Transwell assay (H). Data are shown as mean ± SD from 3 independent experiments. **P < .01 vs miR-19a-5p mimics group. n.s., P > .05
cells. As shown in
suppressed U87MG and U251MG cell proliferation. Additionally, we found that upregulation of AC016405.3 inhibited the metastatic ability U87MG and U251MG cells ( Figure 2E-H imis.athena-innovation.gr), we first measured the expression of the top 12 high binding score (score >0.9) miRNAs that might bind to AC016405.3 ( Figure S2 ) in the collected three freshly frozen GBM tissue specimens. As shown in Figure 3A , miR-19a-5p was stably highly expressed in the 3 collected freshly frozen GBM tissue specimens and thus selected for further study. According to another analysis of GEO dataset GSE103228, miR-19a-5p was upregulated in 5 GBM samples compared to 5 normal brain samples ( Figure 3B ). Additionally, we measured the expression of miR-19a-5p at a cellular level. As the data show in Figure 3C , miR-19a-5p was also upregulated in U87MG and U251MG cells compared to NHA. Furthermore, we found that miR19a-5p was negatively correlated with AC016405.3 ( Figure 3D ). We illustrated that miR-19a-5p and AC016405.3 suppressed each other in a reciprocal manner ( Figure 3E,F) . We also found that an increase of miR-19a-5p partially reversed the suppressive effect that upregulation of AC016405.3 had on U87MG and U251MG cell proliferation and metastasis ( Figure 3G-J) . Finally, using a luciferase assay, we illustrated that miR-19a-5p could directly bind to AC016405.3 through the theoretical miRNA response element ( Figure 3K -M).
| MicroRNA-19a-5p promoted proliferation and metastasis by targeting suppression of TET2 in U87MG and U251MG cells
According to the outcomes of our present research and previous studies, miR-19a-5p works as an oncogene in GBM. 20, 22, 23 Here, we tried to explore downstream genes of miR-19a-5p. We knocked down miR-19a-5p by transfecting miR-19a-5p shRNA ( Figure S3) and then compared the differentially expressed gene profiles by microarray analysis. The results indicated 351 genes (fold change cutoff value 2.0) were upregulated in U87MG and U251MG cells with miR-19a-5p knockdown ( Figure 4A and Table S3 ). Among the 351 genes, TET2 was selected for its most significant changes (criteria of LogFC >6 and P < .001) for further study. First, TET2 was found to be downregulated in GBM tissue specimens ( Figure 4B ). Second, upregulation and downregulation of miR-19a-5p were found to negatively regulate TET2 expression ( Figure 4C,D) . Third, miR-19a-5p was able to bind to different sites (positions 302-308, 820-826, 1671-1677, 2053-2059, and 3470-3476) of TET2 by direct targeting ( Figure S4 ).
Finally, a TET2 overexpression plasmid (oeTET2) was functionally displayed to remarkably attenuate the facilitative effect that upregulation of miR-19a-5p had on U87MG and U251MG cell proliferation and metastasis ( Figure 4E-H protein expression ( Figure 5A ). Second, we found that the expression of TET2 was positively correlated with AC016405.3 ( Figure 5B ).
In addition, we found that when the theoretical miR-19a-5p response 
| D ISCUSS I ON
Accumulative evidence has indicated that lncRNAs are ectopically with I-BET151 treatment abrogates the antiproliferative activity of the BET bromodomain inhibitor. 27 Shi et al found that lncRNA As a novel anti-oncogene, TET2 belongs to the TET family and is located at chromosome 4q24. It is most frequently mutated in several solid malignancies and is closely correlated with DNA methylation. 31 Zhu et al reported that TET2 inhibited tumorigenesis of MCF-7 cells by regulating caspase-4. 32 Chen et al found that TET2 was frequently downregulated in glioma and that ectopic expression of TET2 inhibited the invasion and proliferation of glioma cells. 33 In the present study, we found that the expression of TET2 was most significantly changed after miR-19a-5p knockdown in GBM cells. We further elucidated that TET2 was downregulated in GBM at the tissue level. As a downstream target of miR-19a-5p, ectopic overexpression of TET2 remarkably abrogated the facilitative effect of miR-19a-5p on GBM. These findings indicated that TET2 worked as an antioncogene in GBM. Also, the expression of TET2 and AC016405.3
was shown to present an obvious positive correlation. TET2 was positively regulated by AC016405.3. Finally, a wild AC016405.3 overexpression plasmid was shown to promote TET2 expression, and it mediated proliferation and metastasis; when the MREs19a-5p in AC016405.3 was mutated, the promotive effect was reversed. Taken as a whole, as the diagram explains in Figure 6 , all the outcomes presented in the current research indicated that F I G U R E 6 Schematic diagram of mechanism of this research. miR, microRNA AC016405.3 was an anti-oncogene in GBM, and it suppressed TET2-mediated proliferation and metastasis by competitively sponging miR-19a-5p.
In conclusion, AC016405.3, a novel lncRNA, was identified as an anti-oncogenic lncRNA in GBM. We uncovered a novel pathway in which AC016405.3 sponges miR-19a-5p to modulate TET2-mediated GBM proliferation and metastasis. Our findings indicated a new molecular axis in the treatment of GBM.
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